

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Tsutomu ARAKAWA et al.)	Group Art Unit: 1642
)	
Application No.: 09/994,068)	Examiner: Laura B. GODDARD
)	
Filed: November 27, 2001)	
)	
For: ANTIBODY-INDUCED)	Confirmation No.: 8561
APOPTOSIS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER WITH INTERVIEW SUMMARY

Sir:

Applicants' representative wishes to thank Examiner Goddard for the courtesies extended during the telephone interviews of September 23, 2007; September 24, 2007; and September 25, 2007.

Examiner's Amendments

In the telephone interviews, the pending claims were discussed. The Examiner proposed amending claim 19 to recite "a monoclonal antibody." The Examiner further proposed that claim 20 be cancelled. Applicants' representative agreed to those amendments.

The Examiner also requested that a Terminal Disclaimer over U.S. Patent No. 6,458,356 be filed. We enclose a Terminal Disclaimer over U.S. Patent No. 6,458,356.

Finally, the Examiner requested that a copy of the ATCC Deposit Receipt for hybridoma cell line ATCC No. HB 12078 be filed. We enclose a copy of that ATCC Deposit Receipt.

Conclusion

Applicants assert that the the application is in condition for allowance and respectfully request that the Examiner issue a timely Notice of Allowance. If the Examiner does not consider the present application to be allowable, the undersigned requests that, prior to taking action, the Examiner call her at (650) 849-6611 to set up an interview.

Please grant any extensions of time required to enter this letter and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 26, 2007

By: Elisabeth Jaffe Barek
Elisabeth Jaffe Barek
Reg. No. 46,797
Customer No. 22,852